1FDA.Guidance for industry premarketing risk assessment[EB/OL].http://www.fda.gov/cder/guidance/6357fnl.pdf,2005-03-01.
2ICH E1A.The extent of population exposure to assess clinical safetyfor drugs intended for long-term treatment of non-life-threatening conditions[EB/OL].http://www,fda.gov/cder/guidance/ichela,pdf,1995-O3-01.
3FDA.Guidance for industry good pharmacovigilance practices and pharmacoepide miologic assessment[EB/OL] http://www.fda.gov/cder/guidance/6359OCC,pdf,2005-03-01.
4FDA.Guidance for industry development and use of risk minimization action plans[EB/OL].http://www,fda.gov/cder/guidance/6358fnl.pdf,2005-03-01.
8EMEA.Guideline On Risk Management Systems for MedicinalProducts for Human Use[EB/OL].[2009-10-03].http://www.emea.Europa.eu/pdfs/human/euleg/9626805en.pdf.